Virksomhedsform
Kommanditselskab
Etableret
2007
Størrelse
Mikro
Ansatte
-
Omsætning
- DKK
Bruttofortj.
-73.000 DKK
Primært resultat (EBIT)
-1.233.000 DKK
Årets resultat
-11.971.000 DKK
Egenkapital
559 MDKK
annonce

Flere nøgletal og analyser?

Med en Bisbase Premium konto får du flere nøgletal for både virksomheder, koncerner og brancher samt adgang til eksklusive brancher indeholdende virksomheder nøje sammensat af eksperter. Og vil du lave dine egne analyser kan du også det! Det tager få minutter at få adgang - og det behøver ikke at koste dig noget!

Stamoplysninger baseret på CVR

NavnSunstone Life Science Ventures Fund I K/S
CVR30589416
AdresseStore Strandstræde 18A, 1255 København K
BrancheVentureselskaber og kapitalfonde [643040]
Etableret/nedlagt08-05-2007 - 22-03-2021 (13 år)
Første regnskabsperiode08-05-2007 til 31-12-2007
VirksomhedsformKommanditselskab
Antal ansatte-
ReklamebeskyttelseNej
Regnskabsperiode01-01 til 31-12
Vedtægter seneste31-03-2014

Medlem af brancherne

Regnskab

 202020192018
Valuta/enhed000' DKK000' DKK000' DKK
Omsætning
-
-
-
-
-
-
Bruttofortjeneste
-73
-
-260
-
-150
-
Årets resultat
-11.971
-
355.539
+15.140%
2.333
-
Egenkapital
559.096
-4%
584.023
+32%
442.102
-1%
Balance
559.132
-4%
584.059
+32%
442.165
-1%

Ledelsesberetning

Development in activities and finances​The Fund was established 8 May 2007 as a spinout of 19 portfolio companies in Vækstfonden. At the end of
2020, the Fund holds 1 active portfolio enterprise.

​The result for the year showed a loss of DKK 12 million, which is primarily related to fair value loss from its
investments in portfolio companies.

The following development has taken place during the year:
Symphogen A/S: Located in Denmark, develops next-generation antibody therapeutics for the treatment of
cancer. The company is dedicated to bringing truly innovative oncology products to market, creating optimally
selected antibody mixtures that address multiple oncology targets in a single drug product.
​Symphogen was sold to Servier during the year in return for a performance based earn-out structure.

​Zealand Pharma A/S: Located in Søborg, Denmark, specializes in the discovery, optimization and development of
novel peptide drugs and with broad and mature pipeline of drug candidates identified through the company’s
own drug discovery activities. The company is listed on Nasdaq OMX Copenhagen and news about the company
can be found on www.zealandpharma.com/zealand-news/.
25-01-2021

Kort